Popular Stories

FDA Tag

  • All
  • Beauty
  • Biotechnology
  • Cannabis
  • Communications
  • Education
  • Energy
  • Entertainment
  • Environment
  • ETFs
  • Finance
  • Fitness
  • Food and Beverage
  • Healthcare
  • Hospitality
  • Insider Trading
  • Investing Ideas
  • Macro
  • Market Insight
  • Miscellaneous
  • Power
  • Real Estate
  • Retail
  • Sectors
  • Security
  • Startups
  • Technologies
  • Trending
  • Uncategorized
Can Nektar Therapeutics Bounce Back from its Massive Tumble?

Nektar Therapeutics (NASDAQ: NKTR), a biopharmaceutical Company engaged in developing candidates for oncology, auto-immune and chronic pain, has announced the withdrawal of its application for oxycodegol (formerly NKTR-181), as it received adverse advisory committee decision from both Anesthetic and Analgesic Drug Products Advisory Committee, and...

Conformis Next Generation Hip System Granted FDA Clearance

Conformis Inc (NASDAQ: CFMS), a medical technology company dealing in Knee and Joint replacements, has announced the clearance of its next generation Conformis Hip System by the FDA. The Company’s leading-edge patient-specific arthroplasty joint replacement implants, moulded to suit each patient’s unique anatomy, are developed...

KushCo Holding Forays into New Hemp Trading Business

KushCo Holdings (OTCQX: KSHB), a leading player in the Cannabis-based ancillary industry, announced its foray into Hemp Trading, with a focus on acting as a bridge between buyers and sellers of Hemp Commodities. The move is an attempt to expand its CBD footprint by facilitating...

Cyclerion Therapeutics Praliciguat Fails in Two Crucial Clinical Trials

Cyclerion Therapeutics (NASDAQ: CYCN), a clinical-stage Company, announced the failure of its drug candidate praliciguat in meeting the primary endpoints in two separate clinical studies, in diabetic nephropathy (DN) and heart failure with preserved ejection fraction (HFpEF). Praliciguat is a soluble guanylate cyclase (sGC) stimulator...

WordPress Video Lightbox Plugin